Article info

Download PDFPDF
Immunomodulation and entry inhibition: selgantolimod’s double punch against hepatitis B virus

Authors

  • Thomas Baumert Inserm UMR_S1110, University of Strasbourg, Strasbourg, France Hepatology-Gastroenterology Service, Strasbourg University Hospitals, Strasbourg, France Institute for Translational Medicine and Liver Disease, University of Strasbourg, Strasbourg, France PubMed articlesGoogle scholar articles
  • Melanie Urbanek-Quaing Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany Centre for Individualised Infection Medicine (CiiM), Hannover, Germany PubMed articlesGoogle scholar articles
  • Markus Cornberg Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany Centre for Individualised Infection Medicine (CiiM), Hannover, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Markus Cornberg, Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; cornberg.markus{at}mh-hannover.de
View Full Text

Citation

Baumert T, Urbanek-Quaing M, Cornberg M
Immunomodulation and entry inhibition: selgantolimod’s double punch against hepatitis B virus

Publication history

  • Received June 10, 2024
  • Accepted June 11, 2024
  • First published July 5, 2024.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.